Table 3.
Pharmacokinetic studies of rituximab using pharmacokinetic modelling
| Study | Year | Disease | Nonlinear elimination | Antigen mass | V1 (L) | CL (L/day) | T½‐β (days) |
|---|---|---|---|---|---|---|---|
| Regazzi | 2005 | FL | – | – | 2.98 | 0.208 | 22.4 |
| Blasco | 2008 | DLBCL | – | – | 1.77 | 0.117 | 94.1 |
| Muller | 2012 | DLBCL | – | – | 3.88 | 0.226 | 53.9 |
| Rozman | 2017 | DLBCL | Time‐varying | Disease progression on kdes | 4.62 | 0.252 | 40.3 |
| Tout | 2017 | DLBCL | – | Tumour volume on V1 and V2 | 6.4 | 0.55 | 12.8 |
| Gota | 2016 | DLBCL | – | – | 0.95 | 0.141 | 11.2 |
| Candelaria | 2018 | DLBCL | – | – | 3.19 | 0.3 | 21.2 |
| Li | 2012 | CLL | Time‐varying | – | 4.15 | 0.171 | 26.7 |
| Tout | 2016 | CLL | TMDD | Circulating CD20 on kdeg | 3.08 | 0.137 | 31.3 |
| Ng | 2006 | RA | – | – | 2.98 | 0.257 | 20.2 |
| Lioger | 2017 | RA | Time‐varying | CD19 count on k10 | 4 | 0.44 | 18.5 |
| Puisset | 2013 | Plasma‐pheresis | – | – | 2.48 | 0.15936 | 22.8 |
All pharmacokinetic models were bicompartmental.
FL: follicular lymphoma; DLBCL, diffuse large B‐cell lymphoma; CLL: chronic lymphocytic leukaemia; RA, rheumatoid arthritis; TMDD, target‐mediated drug disposition; V1, V2: central and peripheral volumes of distribution; CL: clearance; k10: first‐order elimination rate constant; kdes: time‐varying elimination rate; kdeg: second‐order target‐mediated elimination rate; T½‐β: elimination half‐life.